HCWB | tickerfilter.com

Fundamental analysis

41%

Profitability 35%

Dept financing 40%

Liquidity 27%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-6.05%

1 Month

-40.94%

3 Months

-68.52%

6 Months

-83.72%

1 Year

72.63%

2 Year

-62.87%

Key data

Stock price

$0.62

P/E Ratio

0.00

DAY RANGE

$0.62 - $0.74

EPS

-$2.24

52 WEEK RANGE

$0.20 - $17.80

52 WEEK CHANGE

$72.63

MARKET CAP

7.961 M

YIELD

N/A

SHARES OUTSTANDING

2.702 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-14-2025

BETA

-0.89

PUBLIC FLOAT

AVERAGE 10 VOLUME

$238,136

AVERAGE 30 VOLUME

$164,047

Company detail

CEO: Hing C. Wong
Region: US
Website: hcwbiologics.com
Employees: 40
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

HCW Biologics Inc. focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. Its lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis. HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia.

HCWB - HCW Biologics Inc.